By Condition & GoalA clinical, evidence-first review of the peptides marketed to older adults for healthspan, muscle and cognition — ranked by what human data actually show, with the honest gap between the marketing and the science.
By Condition & Goal13 MIN READ
Peptide EncyclopediaA clinical monograph on CJC-1293 — an abandoned albumin-binding GHRH analog from the ConjuChem program that produced CJC-1295. No dedicated human data exist; the evidence grade is D, and it is explicitly banned by WADA.
Peptide Encyclopedia10 MIN READ
Peptide EncyclopediaA clinical monograph on sermorelin — the GHRH(1-29) growth-hormone secretagogue once FDA-approved for diagnosis and pediatric GH deficiency. Real but modest, mostly pre-2000 human trials; the anti-aging marketing outruns the data.
Peptide Encyclopedia11 MIN READ
Peptide EncyclopediaA clinical monograph on CJC-1295 without DAC (Mod GRF 1-29) — the short-acting, pulse-preserving GHRH analog. Solid preclinical pharmacology, no human RCT of the no-DAC molecule, and an unsettled 2026 legal status.
Peptide Encyclopedia11 MIN READ
Peptide EncyclopediaA clinical monograph on CJC-1295 with DAC — the albumin-tethered, long-acting GHRH analog. Small Phase 1 RCTs prove it raises GH and IGF-1 for days (Grade B), but no clinical-outcome trial exists, and it is unapproved and banned in sport.
Peptide Encyclopedia11 MIN READ